Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...3435363738394041424344...143144»
  • ||||||||||  subasumstat (TAK-981) / Takeda
    Enrollment closed, Trial completion date, Trial primary completion date:  Intratumoral Microdosing of TAK-981 in Head and Neck Cancer (clinicaltrials.gov) -  Jun 1, 2022   
    P1,  N=12, Active, not recruiting, 
    The combination of cetuximab and nivolumab is effective in patients with both previously treated and untreated R/M HNSCC and warrants further evaluation. Recruiting --> Active, not recruiting | Trial completion date: Nov 2021 --> Jul 2022 | Trial primary completion date: Nov 2021 --> Jun 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment open, Enrollment change, Trial initiation date, Metastases:  Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma (clinicaltrials.gov) -  Jun 1, 2022   
    P2,  N=15, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Nov 2021 --> Jul 2022 | Trial primary completion date: Nov 2021 --> Jun 2022 Not yet recruiting --> Recruiting | N=29 --> 15 | Initiation date: Sep 2022 --> May 2022
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Hypomagnesemia and Hypokalemia: Considerations for Cancer Care. (Pubmed Central) -  May 31, 2022   
    In symptomatic cases of electrolyte deficiency, oral and IV formulations of potassium and magnesium are options for treatment. This article discusses the importance of identifying and understanding the etiologies, symptoms, and treatment modalities of hypomagnesemia and hypokalemia.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer. (Pubmed Central) -  May 30, 2022   
    Should more tolerable combinations be identified, development in an earlier line of therapy and prospective evaluation of the FAT1 hypothesis warrant consideration. Our results suggest that EGFR R521K, unlike reported previously, is unable to cause cetuximab resistance in HNSCC patients; therefore, its screening before therapy selection is not justifiable.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, CAR T-Cell Therapy, IO biomarker:  Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas. (Pubmed Central) -  May 18, 2022   
    Finally, we demonstrated that the new cetuximab CAR construct expressed on T-cells is highly reactive against EGFR-positive HNSCCs and also malignant cells from other solid cancer entities. In conclusion, we generated an optimized high-affinity EGFR CAR construct for the next steps in cancer immunotherapy, which need to focus on the development of armored CAR T-cells that will be more resistant and effective in the hostile microenvironment present in solid cancers.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tepmetko (tepotinib) / EMD Serono
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases:  Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) (clinicaltrials.gov) -  May 18, 2022   
    P2,  N=3, Terminated, 
    First-line treatment with pembrolizumab or pembrolizumab plus chemotherapy are cost-effective strategies compared with cetuximab plus chemotherapy when the value of willingness-to-pay (WTP) was $150000 per QALY for the total and PD-L1 CPS ≥ 1 populations with recurrent or metastatic HNSCC. N=48 --> 3 | Trial completion date: Mar 2023 --> Mar 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2023 --> Mar 2022; The study was terminated early due to operational challenges identifying suitable participants for screening in the study.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical, Journal, PD(L)-1 Biomarker, IO biomarker:  Nivolumab for recurrent/metastatic hypopharyngeal squamous cell carcinoma in a liver transplant recipient. (Pubmed Central) -  May 17, 2022   
    While using oral immunosuppressants (cyclosporine and mycophenolate mofetil), the patient underwent right neck dissection followed by radiotherapy as an initial treatment...We administered two courses of the EXTREME regimen, comprising cisplatin, 5-fluorouracil, and cetuximab, as the first-line treatment for distal metastasis, but the patient presented with progressive disease...Although liver dysfunction was alleviated by adjusting the dose of the hepatoprotective agent and cyclosporine, the progressive disease status persisted after completing nivolumab courses. The patient died of hypopharyngeal cancer progression.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    New P1 trial, Surgery:  GLANS: Image Guided Penile Cancer Surgery (clinicaltrials.gov) -  May 16, 2022   
    P1,  N=15, Recruiting, 
  • ||||||||||  Libtayo (cemiplimab) / Sanofi, Regeneron, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal, Tumor Mutational Burden, PD(L)-1 Biomarker:  High-risk cutaneous squamous cell carcinoma (CSCC): Challenges and emerging therapies. (Pubmed Central) -  May 14, 2022   
    The response rate varies based on the patient, although there is still a lack of proof. This article discusses the misconception that CSCC is a tumor with a favorable prognosis, as well as the difficulties in treating high-risk CSCC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Meditopia: Meditope-Enabled Bonds and their Affinity with Cetuximab. (Pubmed Central) -  May 14, 2022   
    The Mahtomedi MSOE Center for BioMolecular Modeling MAPS Team will use 3-D modeling and printing technology to examine structure-function relationships of meditope-mAb binding within cetuximab. The visual model will be a valuable tool in developing our story.